FindTrial
Sign In

18F-rhPSMA-7.3

DRUG4 trials

Sponsors

University of Alabama at Birmingham, Brigham and Women's Hospital, Hackensack Meridian Health, Washington University School of Medicine

Conditions

Hormone Sensitive Prostate CancerMetastatic Hormone-sensitive Prostate Cancer (mHSPC)Metastatic Prostate CancerProstate CancerProstate Cancer MetastaticProstate Cancer RecurrentRecurrent Prostate Cancer

Early Phase 1

18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study
WithdrawnNCT05707182
University of Alabama at BirminghamProstate Cancer
Start: 2025-04-30End: 2026-12-31Updated: 2024-09-25

Phase 2

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
Not yet recruitingNCT07593079
Washington University School of MedicineMetastatic Prostate Cancer, Prostate Cancer, Prostate Cancer Metastatic +2
Start: 2026-10-31End: 2028-01-31Target: 20Updated: 2026-09-11

Phase 4

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
Active, not recruitingNCT06479187
Brigham and Women's HospitalHormone Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Metastatic Prostate Cancer
Start: 2024-06-30End: 2027-06-20Target: 20Updated: 2025-11-05

Unknown Phase

Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
RecruitingNCT07011342
Hackensack Meridian HealthProstate Cancer
Start: 2025-10-01End: 2028-11-01Target: 70Updated: 2026-03-23

Related Papers

Quantitative results from PSMAtrack: A prospective study evaluating changes in PSMA-PET during initial systemic therapy for metastatic hormone-sensitive prostate cancer (mHSPC).
Journal of Clinical Oncology2026-05-27